Structure modeling of the chemokine receptor CCR5: Implications for ligand binding and selectivity

被引:71
|
作者
Paterlini, MG
机构
[1] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Inst Supercomp, Minneapolis, MN 55455 USA
关键词
D O I
10.1016/S0006-3495(02)75307-1
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The G-protein coupled receptor CCR5 is the main co-receptor for macrophage-tropic HIV-1 strains. I have built a structural model of the chemokine receptor CCR5 and used it to explain the binding and selectivity of the antagonist TAK779. Models of the extracellular (EC) domains of CCR5 have been constructed and used to rationalize current biological data on the binding of HIV-1 and chemokines. Residues spanning the transmembrane region of CCR5 have been modeled after rhodopsin, and their functional significance examined using the evolutionary trace method. The receptor cavity shares six residues with CC-chemokine receptors CCR1 through CCR4, while seven residues are unique to CCR5. The contribution of these residues to ligand binding and selectivity is tested by molecular docking simulations of TAK779 to CCR1, CCR2, and CCR5. TAK779 binds to CCR5 in the cavity formed by helices 1, 2, 3, and 7 with additional interactions with helices 5 and 6. TAK779 did not dock to either CCR1 or CCR2. The results are consistent with current site-directed mutagenesis data and with the observed selectivity of TAK779 for CCR5 over CCR1 and CCR2. The specific residues responsible for the observed selectivity are identified. The four EC regions of CCR5 have been modeled using constrained simulated annealing simulations. Applied dihedral angle constraints are representative of the secondary structure propensities of these regions. Tertiary interactions, in the form of distance constraints, are generated from available epitope mapping data. Analysis of the 250 simulated structures provides new insights to the design of experiments aimed at determining residue-residue contacts across the EC domains and for mapping CC-chemokines on the surface of the EC domains.
引用
收藏
页码:3012 / 3031
页数:20
相关论文
共 50 条
  • [21] Characterisation of chemokine triggered internalisation and phosphorylation of the chemokine receptor CCR5
    Mueller, A
    Strange, PG
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134
  • [22] A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimer: binding affinity versus functional activities
    Yuan, Yunyun
    Arnatt, Christopher K.
    El-Hage, Nazira
    Dever, Seth M.
    Jacob, Joanna C.
    Selley, Dana E.
    Hauser, Kurt F.
    Zhang, Yan
    MEDCHEMCOMM, 2013, 4 (05) : 847 - 851
  • [23] In vitro pharmacoregulation of CC chemokine ligand 5 and its receptor CCR5 in diffuse lung diseases
    Sekerova, V
    Subrtova, D
    Mrazek, F
    Gibejova, A
    Kolek, V
    du Bois, RM
    Petrek, M
    MEDIATORS OF INFLAMMATION, 2003, 12 (04) : 215 - 220
  • [24] The expression of the chemokine receptor CCR5 in psoriasis and the results of a randomized placebo controlled trial with a CCR5 receptor inhibitor
    de Groot, M.
    Teunissen, M. B.
    Picavet, D., I
    Arreaza, M. G.
    Simon, J. S.
    Kraan, M.
    Bos, J. D.
    de Rie, M. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 59 - 59
  • [25] The expression of the chemokine receptor CCR5 in psoriasis and the results of a randomized placebo controlled trial with a CCR5 receptor inhibitor
    de Groot, M.
    Picavet, D. I.
    de Rie, M. A.
    Teunissen, M. B.
    Bos, J. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S39 - S39
  • [26] Structure-function relationships of CCR5 as a chemokine receptor and HIV co-receptor
    Parmentier, M
    Samson, M
    Libert, F
    Cochaux, P
    Rucker, J
    Doranz, BJ
    LaRosa, G
    Paindavoine, P
    Detheux, M
    Blanpain, C
    Govaerts, C
    Maho, A
    Doms, RW
    Vassart, G
    11E COLLOQUE DES CENT GARDES: RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 1998, : 55 - 59
  • [27] The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density
    Desmetz, Caroline
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Rabesandratana, Herisoa
    Clot, Jacques
    Corbeau, Pierre
    IMMUNOLOGY, 2006, 119 (04) : 551 - 561
  • [28] Clinical studies with chemokine receptor-5 (CCR5)-inhibitors
    Boesecke, Christoph
    Pett, Sarah L.
    CURRENT OPINION IN HIV AND AIDS, 2012, 7 (05) : 456 - 462
  • [29] Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex
    Tan, Qiuxiang
    Zhu, Ya
    Li, Jian
    Chen, Zhuxi
    Han, Gye Won
    Kufareva, Irina
    Li, Tingting
    Ma, Limin
    Fenalti, Gustavo
    Li, Jing
    Zhang, Wenru
    Xie, Xin
    Yang, Huaiyu
    Jiang, Hualiang
    Cherezov, Vadim
    Liu, Hong
    Stevens, Raymond C.
    Zhao, Qiang
    Wu, Beili
    SCIENCE, 2013, 341 (6152) : 1387 - 1390
  • [30] A hammerhead ribozyme targeted to the human chemokine receptor CCR5
    González, MA
    Serrano, F
    Llorente, M
    Abad, JL
    García-Ortiz, MJ
    Bernad, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 251 (02) : 592 - 596